MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.860
-0.110
-5.58%
Opening 10:57 09/20 EDT
OPEN
1.880
PREV CLOSE
1.970
HIGH
1.918
LOW
1.855
VOLUME
159.26K
TURNOVER
--
52 WEEK HIGH
5.42
52 WEEK LOW
1.750
MARKET CAP
28.48M
P/E (TTM)
-1.1359
1D
5D
1M
3M
1Y
5Y
Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Execut...
GlobeNewswire · 09/08 11:00
Why Is Plus Therapeutics Stock Moving Higher On Thursday?
Benzinga · 09/02 13:48
Sector Update: Health Care Stocks Gaining Steam in Thursday Trading
MT Newswires · 09/02 13:38
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
BRIEF-Plus Therapeutics Announces Commercial Manufacturing Supply Agreement For Its Lead Investigational Drug
reuters.com · 09/02 11:45
Plus Therapeutics Reports Commercial Manufacturing Supply Deal For Its Lead Investigational Drug, No Terms Disclosed
RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production RadioMedix will produce cGMP drug product for Rhenium-186 NanoLiposome (186RNL) and
Benzinga · 09/02 11:02
Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug
RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production RadioMedix will produce cGMP drug product for Rhenium-186 NanoLiposome (186RNL) and may extend to future products under t...
GlobeNewswire · 09/02 11:00
Plus Therapeutics Signs Commercial Manufacturing Supply Deal With RadioMedix - Shares Rise Pre-Bell
MT Newswires · 09/02 09:34
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTV. Analyze the recent business situations of Plus Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTV stock price target is 6.88 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 1.61M
% Owned: 10.52%
Shares Outstanding: 15.31M
TypeInstitutionsShares
Increased
5
791.14K
New
9
532.84K
Decreased
2
1.52K
Sold Out
5
14.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.50%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Chairman/Director
Richard Hawkins
President
Steven Kesten
Chief Executive Officer/Director
Marc Hedrick
Chief Financial Officer/Vice President - Finance
Andrew Sims
Corporate Executive
Seijiro Shirahama
Senior Vice President
Gregory Stein
Chief Accounting Officer/Controller
Desiree Smith
Vice President - Business Development/General Counsel
Jeremy Hayden
Other
Norman LaFrance
Other
Mark Marino
Independent Director
Howard Clowes
Independent Director
Robert Lenk
Independent Director
Greg Petersen
Independent Director
Annigje van Es-Johansson
No Data
About PSTV
Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

Webull offers kinds of Plus Therapeutics Inc stock information, including NASDAQ:PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.